Weyandt Lisa L, Oster Danielle R, Marraccini Marisa E, Gudmundsdottir Bergljot Gyda, Munro Bailey A, Rathkey Emma S, McCallum Alison
Department of Psychology.
Alpert Medical School of Brown University.
Exp Clin Psychopharmacol. 2016 Oct;24(5):400-414. doi: 10.1037/pha0000093.
Prescription stimulants, including methylphenidate (e.g., Ritalin) and amphetamine compounds (e.g., dextroamphetamine; Adderall), have been approved by the U.S. Food and Drug Administration for the treatment of attention-deficit/hyperactivity disorder (ADHD) and are classified by the United States Drug Enforcement Administration as Schedule II medications because of their high potential for abuse and dependence (Drug Enforcement Administration, U.S. Department of Justice, 2015). Despite the potential health and judicial consequences, misuse of prescription stimulants, typically defined as taking stimulants without a valid prescription, or use of stimulants other than as prescribed, has become a serious problem in the United States and abroad, especially on college campuses. The purpose of the present article is to review historical information concerning prescription stimulants and to summarize the literature with respect to misuse among adults, particularly college students, including risk factors, mediators and moderators, and motivations for prescription stimulant misuse. In addition, evidence is presented concerning the question of whether prescription stimulants truly enhance cognitive functioning in individuals with and without ADHD, and the ethical and professional implications of these findings are explored. Lastly, recommendations for addressing prescription stimulant misuse and suggestions for future research are advanced. (PsycINFO Database Record
处方兴奋剂,包括哌甲酯(如利他林)和苯丙胺类化合物(如右旋苯丙胺;阿得拉),已获美国食品药品监督管理局批准用于治疗注意力缺陷多动障碍(ADHD),并被美国缉毒局列为第二类药物,因为它们具有很高的滥用和成瘾潜力(美国缉毒局,美国司法部,2015年)。尽管存在潜在的健康和司法后果,但处方兴奋剂的滥用,通常定义为在没有有效处方的情况下服用兴奋剂,或不按规定使用兴奋剂,已在美国国内外成为一个严重问题,尤其是在大学校园。本文的目的是回顾有关处方兴奋剂的历史信息,并总结关于成年人,特别是大学生滥用情况的文献,包括风险因素、中介因素和调节因素,以及处方兴奋剂滥用的动机。此外,还提供了关于处方兴奋剂是否真的能提高患有和未患有ADHD的个体认知功能这一问题的证据,并探讨了这些发现的伦理和专业意义。最后,提出了应对处方兴奋剂滥用的建议和未来研究的建议。(PsycINFO数据库记录)